Skip to main navigation
Skip to search
Skip to main content
Prinses Máxima Centrum Home
Nederlands
English
Search content at Prinses Máxima Centrum
Home
Profiles
Research Groups
Equipment
Research output
Prizes
Activities
Press/Media
Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
Jakob K. Anninga
, Hans Gelderblom
,
Marta Fiocco
, Judith R. Kroep
, Antoni H.M. Taminiau
, Pancras C.W. Hogendoorn
, R. Maarten Egeler
Research output
:
Contribution to journal
›
Article
›
peer-review
401
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Adjuvant Therapy
100%
Osteosarcoma
100%
Drug Regimen
100%
Chemotherapy Adjuvant
100%
Meta-analysis
75%
High-grade Osteosarcoma
75%
Confidence Interval
50%
Event-free Survival
50%
Cisplatin
50%
Ifosfamide
50%
Methotrexate
50%
Adriamycin
50%
Two-drug Regimen
50%
Chemotherapy
25%
Overall Survival
25%
Etoposide
25%
Long-term Survival
25%
5-year Survival
25%
No Significant Difference
25%
Phase II Study
25%
Poor Responders
25%
Systematic Literature Review
25%
Non-randomized Trial
25%
Adjuvant Chemotherapy
25%
Local Treatment
25%
Conventional Chemotherapy
25%
Post-chemotherapy
25%
Salvage Treatment
25%
High Response Rate
25%
Number of Drugs
25%
Neoadjuvant
25%
Response-adapted
25%
Systematic Review Evidence
25%
Nursing and Health Professions
Chemotherapy
100%
Adjuvant Therapy
100%
Osteosarcoma
100%
Meta Analysis
75%
Confidence Interval
50%
Cisplatin
50%
Overall Survival
50%
Doxil
50%
Event Free Survival
50%
Methotrexate
50%
Ifosfamide
50%
Systematic Review
25%
Local Therapy
25%
Etoposide
25%
Long Term Survival
25%
Adjuvant Chemotherapy
25%
Medicine and Dentistry
Adjuvant Therapy
100%
Osteosarcoma
100%
Meta-Analysis
75%
Chemotherapy
75%
Event Free Survival
50%
Overall Survival
50%
Cisplatin
50%
Doxorubicin
50%
Ifosfamide
50%
Methotrexate
50%
Clinical Study
50%
Systematic Review
25%
Etoposide
25%
Long Term Survival
25%
Local Therapy
25%
Adjuvant Chemotherapy
25%
Biochemistry, Genetics and Molecular Biology
Cisplatin
100%
Overall Survival
100%
Ifosfamide
100%
Event Free Survival
100%
Clinical Study
100%
Doxorubicin
100%
Methotrexate
100%
Long Term Survival
50%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Osteosarcoma
100%
Event Free Survival
50%
Overall Survival
50%
Doxorubicin
50%
Ifosfamide
50%
Cisplatin
50%
Clinical Study
50%
Methotrexate
50%
Etoposide
25%
Long Term Survival
25%